MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action

Liposarcomas (LPS) are rare mesenchymal neoplasms that arise from lipocytes in soft tissues. LPS account for approximately 15% to 20% of all soft tissue sarcomas in adults [1,2]. LPS may arise in any anatomic site; the most common locations are the retroperitoneum and extremities [3,4]. In 2016, the incidence of liposarcoma in the United States was approximately 1 per 100,000 person-years [3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research